Detail akcie Ocular Therapeutix online

Business Summary: Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Ocular Therapeutix Inc revenues increased less than 1% to $24.3M. Net loss increased 27% to $167.4M., also reflect Collaboration revenue decrease from $128K to $0K. Higher net loss reflects ophthalmology segment loss increase of 33% to $175.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.77103 to -$0.74554.